Wednesday, September 16, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Sep 15, 2026
FDA launches pilot program to speed up sluggish phase 1 trials
background ▾
- •FDA is establishing a structured pilot to compress phase 1 timelines by 6-12 months through dedicated sponsor-QRI partnerships and expedited IND review—a direct response to competitive pressure from China and Australia
- •The program targets sponsors with novel products for severe unmet need diseases and requires substantial preclinical data readiness, limiting initial participant pool but improving quality control
- •Success metrics and generalizability to the broader industry remain unclear; early-stage trial delays are multifactorial (site capacity, patient enrollment, manufacturing), and regulatory review speed may not be the primary constraint
Policy•STAT News•Sep 16, 2026
Opinion: How my cancer diagnosis changed the way I train physicians
background ▾
Policy•STAT News•Sep 16, 2026
Opinion: STAT+: Dementia should be a campaign issue — not an insult
background ▾
- •Dementia affects 7.1 million Americans with 12 million caregivers experiencing significant out-of-pocket costs and lost wages, making it a major healthcare burden that warrants serious policy attention
Policy•Endpoints News•Sep 15, 2026
Klomp, Warren spar over MFN deal contracts
background ▾
- •Congressional oversight of Medicare drug price negotiation implementation continues at senior HHS nomination hearings, signaling sustained policy focus
Policy•Endpoints News•Sep 15, 2026
FDA approves first radioligand generic, setting up rivalry with Novartis
background ▾
- •First generic radioligand approval by FDA marks the beginning of competitive pressure in a previously Novartis-dominated market
- •Radioligand generics entering the market may drive down pricing and expand patient access to this growing therapeutic modality
- •Unclear which specific radioligand received approval and manufacturing/supply chain implications for isotope-dependent generics
CuriumNovartis
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 15, 2026
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
background ▾
- •Lilly commits up to $237M per program in milestones to QurCan's non-viral PLNP delivery platform targeting CNS/PNS genetic medicines, addressing a critical bottleneck in BBB penetration
- •Deal validates QurCan's TERP technology as differentiated solution for genetic medicine delivery and strengthens Lilly's genetic medicine pipeline alongside existing neuroscience assets
- •Monitor program selection and clinical candidate designation; track Lilly's progress on mevidalen and GBA1 gene therapy to understand how this platform integrates with near-term development plans
Eli LillyQurCan TherapeuticsNovartisKisunlamevidalenGBA1 gene therapy
→ Read original articleMarket Access•Fierce Biotech•Sep 15, 2026
Mayo Clinic teams with Thermo Fisher to form biomedical data group Precure
background ▾
- •Precure LLC represents a significant commercial infrastructure play combining diagnostic/research technology with clinical-grade longitudinal data at scale, with potential to reshape early disease detection and drug development timelines
- •The partnership leverages complementary assets: Thermo Fisher's multi-omics technology platforms and Mayo Clinic's decades of curated patient data and clinical credibility, creating a defensible competitive moat
- •Monitor data governance, licensing agreements with pharma/biotech partners, regulatory pathways for any companion diagnostics, and whether competing academic-industry consortia (e.g., All of Us, UK Biobank partnerships) gain comparable data scale and commercial viability
Mayo ClinicThermo Fisher Scientific
→ Read original articleMarket Access•Fierce Biotech•Sep 15, 2026
Newly formed Jaguar acquires Afib device assets from J&J
background ▾
- •J&J divested the Laminar LAA closure program less than two years after acquiring it for $400M, suggesting either strategic portfolio pruning or underperformance relative to internal priorities
- •The asset reconstitution under Jaguar LAA with original development team and Santé Ventures backing suggests confidence in the technology's differentiated catheter-based approach versus competing LAA closure devices
Johnson & JohnsonJaguar LAALaminarLaminar
→ Read original articleMarket Access•Endpoints News•Sep 15, 2026
Why Omada is staying in its lane
background ▾
- •Omada Health achieved first profitable quarter post-IPO, demonstrating path to sustainable economics in digital health
Omada Health
→ Read original articleMarket Access•Endpoints News•Sep 15, 2026
Kairon Health raises $5M to use data to make patients healthier
background ▾
- •Kairon Health secured $5M to scale its patient data analytics platform for value-based care practices
Kairon Health
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 15, 2026
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
background ▾
- •Rademikibart missed asthma phase 2 primary endpoint due to unexpectedly low placebo treatment failure rates, despite showing numerical 66% benefit and statistical significance on secondary FEV1 measure
- •Connect is considering IV formulation for emergency department use and evaluating both IV and subcutaneous development paths for acute populations
- •Upcoming COPD phase 2 topline data (expected end of month) is critical; analysts flagged concerns about study site/enrollment overlap that may limit interpretation of that readout
Connect BiopharmaSimcere PharmaceuticalSanofirademikibartDupixent
→ Read original articleClinical Trials•Fierce Biotech•Sep 15, 2026
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
background ▾
- •SION-719 failed to achieve statistically significant reduction in sweat chloride as an add-on to Trikafta, triggering a 90% stock decline and forcing strategic restructuring
- •Sionna's post hoc analysis attributes failure to trial interpretation factors rather than drug inefficacy, supporting advancement of dual NBD1 stabilizer plus CFTR corrector combination into phase 2
- •Watch phase 2a results for SION-451/SION-2222 combination and whether Sionna can execute on narrowed pipeline with reduced headcount through 2029
Sionna TherapeuticsVertex PharmaceuticalsSION-719SION-451SION-2222
→ Read original articleClinical Trials•Endpoints News•Sep 15, 2026
Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest deal
background ▾
- •Rocket Pharmaceuticals achieved FDA alignment on Danon development strategy, suggesting regulatory pathway clarity for this gene therapy program
Rocket PharmaceuticalsNovoAscendisDanon
→ Read original articleClinical Trials•Endpoints News•Sep 15, 2026
Axoltis says its Phase 2 study for an experimental ALS drug failed
background ▾
- •Phase 2 primary endpoint not achieved, representing a significant setback for Axoltis's ALS program
- •Company identified a potential small signal that could support continued development in specific patient populations or warrant protocol refinement
Axoltis Pharma
→ Read original articleClinical Trials•Fierce Biotech•Sep 15, 2026
GSK doubles down on Chimagen with $750M multiple myeloma wager
background ▾
- •GSK's $750M commitment to Chimagen's trispecific TCE reflects industry-wide conviction that multi-antigen targeting can overcome tolerability barriers that currently limit approved bispecific TCEs to heavily pretreated patients (≥4 prior lines)
- •The trispecific modality is becoming a crowded competitive space with at least three major pharma players (GSK, AbbVie, J&J) pursuing this approach in parallel, suggesting potential for rapid clinical readouts but heightened execution risk
- •Watch for phase 1 safety and pharmacokinetic data from GSK's candidate in 2025, and competitive readouts from AbbVie's CD38/BCMA/CD3 and J&J's phase 3 trispecific trials—any toxicity signal could reset the entire category
GSKChimagen BiosciencesJohnson & JohnsonTecvayliElrexfioLynozyfic
→ Read original article